Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Otsuka Pharmaceutical Co. Ltd.

Division of Otsuka Holdings Co. Ltd.
www.otsuka.co.jp/en/

Latest From Otsuka Pharmaceutical Co. Ltd.

PureTech’s Karuna Gets Another $68m For Re-engineered Lilly CNS Candidate

Karuna Therapeutics plans to expand its development program for lead candidate KarXT beyond its current Phase II trial in schizophrenia. The series B financing follows a $42m series A in 2018.

Financing StartUps and SMEs

Shionogi To Switch Europe HQ Out Of London Over Brexit

The drug maker looks set to join fellow Japanese firms Sony and Panasonic in moving its European legal base out of the UK as the uncertainties surrounding Brexit show little sign of being resolved.

Brexit Strategy

Shionogi Builds Digital Therapeutics Presence Through Akili Alliance

Shionogi has become the latest Japanese company to build its presence in the digital health realm, this time through an alliance with Akili for two novel digital therapeutics.

Japan Business Strategies

J&J Says Bedaquiline TB Treatment Cost ‘Fair,’ $1/Day Price ‘Unrealistic’

Johnson & Johnson maintains its game-changing antibiotic bedaquiline for drug-resistant tuberculosis is priced "fairly" at $400 for a six-month course, and terms calls by public health advocates to cut the cost to $1 a day “not realistic.”

Infectious Diseases Pricing Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register